Baxter International Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Baxter International Inc. on June 1, 2010. The report discloses significant changes in the company's executive leadership structure effective July 5, 2010.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the restructuring of senior executive roles within the Renal division and the Finance department:
- Departure: Bruce H. McGillivray retired as Corporate Vice President and President, Renal.
- Appointment: Robert M. Davis, previously Corporate Vice President and Chief Financial Officer, was elected to succeed Mr. McGillivray as Corporate Vice President and President, Renal.
- Appointment: Robert J. Hombach was elected to succeed Mr. Davis as Chief Financial Officer. His new title is Corporate Vice President, Chief Financial Officer and Treasurer.
Compensation and Outlook
In connection with his election, Mr. Hombach will enter into a standard executive severance agreement and receive a grant of 5,000 restricted stock units under the Company's 2003 Incentive Compensation Program and LTI Stock Option and Restricted Stock Unit Plan. The filing does not provide specific guidance, outlook, or commentary on risks beyond the standard transition of duties.
Investor Verification Checklist
- Confirm the effective date of the leadership transition (July 5, 2010).
- Verify the specific terms of the executive severance agreement for Mr. Hombach.
- Review the impact of the Renal division leadership change on future strategic initiatives.
- Check subsequent filings for any financial impact related to the executive compensation grants.